Galapagos NV (NASDAQ:GLPG) has received a consensus rating of “Hold” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $115.17.
Several equities analysts have recently issued reports on the company. BidaskClub downgraded Galapagos from a “buy” rating to a “hold” rating in a research report on Friday. BTIG Research reiterated a “buy” rating and set a $118.00 price objective on shares of Galapagos in a research report on Thursday, February 8th. ValuEngine upgraded Galapagos from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research downgraded Galapagos from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 25th.
Shares of Galapagos (NASDAQ:GLPG) traded down $1.09 during midday trading on Tuesday, hitting $101.42. The stock had a trading volume of 58,809 shares, compared to its average volume of 104,472. The firm has a market capitalization of $5,220.00, a P/E ratio of -38.54 and a beta of 0.99. Galapagos has a fifty-two week low of $72.48 and a fifty-two week high of $121.09.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Financial Gravity Companies Inc. acquired a new stake in Galapagos in the fourth quarter worth approximately $104,000. Advisors Preferred LLC acquired a new stake in Galapagos in the third quarter worth approximately $105,000. Tower Research Capital LLC TRC lifted its position in Galapagos by 7,340.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,488 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 1,468 shares during the period. Envestnet Asset Management Inc. lifted its position in Galapagos by 156.6% in the third quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 1,063 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Galapagos in the third quarter worth approximately $218,000. Hedge funds and other institutional investors own 19.38% of the company’s stock.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.